文摘
摘要目的:确定定量差异皮质萎缩和海马病理学autopsy-confirmed路易体痴呆与患者(下文)和不可能的快速眼动(REM)行为障碍(RBD),并确定是否海马体积,下文核心功能和RBD是病理的预测下文的可能性。
背景:RBD的特点是协调运动行为在REM睡眠伴随肌肉弛缓的损失。RBD是下文暗示的特点,随着认知障碍,和三个核心特征:帕金森症、波动,和视觉幻觉。路易体有关患者神经病理学尸检往往伴随的阿兹海默氏症,这是与MRI海马萎缩。
设计/方法:连续使用下文财团病理学标准,我们确定了75年由低可能性autopsy-confirmed下文案例来自梅奥诊所的广告研究中心经历了临死前的MRI与probable-RBD (n = 35),没有probable-RBD (n = 40)。病理的负担过度磷酸化neurofibrillary-tau、α-synucleinβ-amyloid海马体是量化。Atlas-based量化海马的数量和分布进行了临死前的核磁共振成像的分析。
结果:海马neurofibrillary-tau (p = 0.007)和β-amyloid负担(p < 0.001)降低,海马和parietotemporal皮质成交量大的那些历史上probable-RBD相比那些没有probable-RBD的历史。一个有序逻辑回归模型和临死前的成像和下文临床特征预测autopsy-confirmed路易体痴呆的发生可能性更大显示趋势海马体积(优势比= 1.13,p = 0.08)和probable-RBD增加了可能性的历史(优势比= 5.78,p = 0.004)预测与DLB-likelihood病理相关。帕金森症模型中找到意义(p = 0.10)和海马体积probable-RBD,但不是波动或视觉幻觉。
结论:存在probable-RBD与少严重阿尔茨海默氏症病理和它们老年痴呆萎缩在下文可能性由低。我们的数据表明,RBD的存在是一个强有力的预测下文的可能性比当前建立的核心特性。
支持:P50 -AG016574/ P1, R01 -AG040042R01 -AG015866R01 -AG011378P50-NS72187 Mangurian基金会,史密斯和vanBuren广告研究项目。
披露:莫瑞没有披露。Ferman博士没有披露。Boeve博士收到头研究支持公司。Allon疗法;和通用电气医疗集团。Przybelski博士没有披露。Lesnick博士已经收到个人赔偿的活动与生殖医学和不孕的同事作为顾问。Liesinger博士没有披露。Vemuri博士没有披露。Senjem博士没有披露。 Dr. Dugger has nothing to disclose. Dr. Knopman has received personal compensation for activities with Eli Lilly & Company. Dr. Knopman has received personal compensation in an editorial capacity for Neurology. Dr. Knopman has received research support from TauRx. Dr. Smith has nothing to disclose. Dr. Parisi has nothing to disclose. Dr. Silber has nothing to disclose. Dr. Graff-Radford has received personal compensation for activities with Codman. Dr. Graff-Radford has received personal compensation in an editorial capacity for the Neurologist. Dr. Graff-Radford has received research support from Janssen, Pfizer Pharmaceuticals, Medivation, Forrest, and Allon. Dr. Petersen has received personal compensation for activities with Pfizer, Inc., Janssen Alzheimer's Immunotherapy, Elan Pharmaceuticals, GE Healthcare, and Novartis. Dr. Jack has received personal compensation for activities with Janssen, Eisai Inc., General Electric, Johnson & Johnson, and Eli Lilly & Company. Dr. Jack has received research support from Pfizer Inc, Allon, and Baxter. Dr. Jack has received research support from Allon and Baxter. Dr. Dickson has received personal compensation for activities with Neotope, Inc. as a consultant. Dr. Kantarci has received compensation from Takeda Global Research & Development Center for serving as an advisory board member for research support.
星期四,2013年3月21日12:00 pm-2:00点
- 版权©2013年长企业公司,。
